c-MET is a receptor tyrosine kinase abnormally activated in many cancer types, such as renal, liver, head and neck, gastroesophageal, breast, and lung cancer (Reis et al., 2018), and activates several intracellular signaling pathways including RAS-MAPK, PI3K-AKT, RAC1, and PAK to promote the progression of cancers (Graveel et al., 2013). This evidence concerns the gene MET and cancer.